Pharmaceuticals News and Research

RSS

FDA update on BYETTA injection: Amylin Pharmaceuticals and Eli Lilly respond

Amylin Pharmaceuticals, Inc., and Eli Lilly and Company today issued the following statement in response to the U.S. Food and Drug Administration (FDA) update on BYETTA® (exenatide) injection.

3 Nov 2009

Pateamine A found to inhibit yet another anti-cancer mechanism

Pateamine A (PatA), a natural product first isolated from marine sponges, has attracted considerable attention as a potential anti-cancer agent, and now a new activity has been found for it, which may reveal yet another anti-cancer mechanism. That's the assessment of Daniel Romo, a Texas A&M chemistry professor, and his colleagues at Johns Hopkins University who are pioneers in research involving this novel marine natural product.

3 Nov 2009

NuPathe and SurModics sign a drug delivery technology license agreement

SurModics, Inc., a leading provider of drug delivery and surface modification technologies to the healthcare industry, and NuPathe Inc., a neuroscience-focused specialty pharmaceutical company, announced today that the companies have entered into a license agreement for drug delivery technology.

3 Nov 2009

FDA updates Byetta prescribing information following reports of kidney problems

The U.S. Food and Drug Administration today acted on new safety information about possible kidney function problems, including kidney failure, in patients taking Byetta (exenatide), a drug used to treat Type 2 diabetes.

3 Nov 2009

Cipher Pharmaceuticals to defend alleged patent infringement of CIP-TRAMADOL ER

Cipher Pharmaceuticals Inc. today announced that Purdue Pharma Products L.P. and Napp Pharmaceutical Group Ltd. have filed a complaint against Cipher in the United States District Court for the Eastern District of Virginia, for alleged infringement of two U.S. patents. The action relates to Cipher's New Drug Application ("NDA") filed with the U.S. Food and Drug Administration ("FDA") for CIP TRAMADOL ER, the Company's extended-release tramadol product.

3 Nov 2009

Top-line results from Phase 3 linaclotide trial for chronic constipation

Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. today announced positive top-line results from two Phase 3 clinical trials assessing the safety and efficacy of once-daily dosing of the investigational drug linaclotide in patients with chronic constipation (CC).

3 Nov 2009

Cancer Cell publishes a paper on ARIAD Pharmaceuticals' Pan-BCR-ABL inhibitor

ARIAD Pharmaceuticals, Inc. today announced that the scientific journal, Cancer Cell, has published a comprehensive paper describing the design and preclinical characterization of AP24534, ARIAD’s investigational, multi-targeted kinase inhibitor.

3 Nov 2009

ART Advanced Research Technologies to secure $1.2M interim financing

ART Advanced Research Technologies Inc., a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, announced that earlier today it filed a notice of intention to make a proposal to its creditors under the Bankruptcy and Insolvency Act with KPMG Inc. in order to provide the company with the liquidity it requires to pursue its solicitation process.

2 Nov 2009

NIH-funded study using SphygmoCor published

AtCor Medical the developer and marketer of the SphygmoCor® system which measures central blood pressure and arterial stiffness noninvasively, today announced the publication of a key National Institutes of Health (NIH)-funded study(1) using SphygmoCor in the Journal of the American College of Cardiology (JACC).

2 Nov 2009

Ligand Pharmaceuticals amends license agreement with Exelixis

Ligand Pharmaceuticals Incorporated has amended its license agreement with Exelixis, Inc. as a result of which Ligand is now entitled to receive royalties on net sales of future products from a mineralocorticoid receptor program and a one-time $75,000 payment for providing access to certain patent rights.

2 Nov 2009

DSPA chooses SAS Solutions OnDemand as a technology platform for clinical development

SAS announced today that Dainippon Sumitomo Pharma America, Inc. (DSPA), a U.S. pharmaceutical company, has selected SAS Solutions OnDemand: Drug Development as a technology platform for clinical development. With SAS OnDemand, DSPA will have a globally accessible, fully regulatory compliant repository for all of its clinical data.

2 Nov 2009

MDS sells its Central Labs operations to Czura Thornton

MDS Inc., a leading provider of products and services to the global life sciences markets, today announced that it has completed the divestiture of its Central Labs operations to Czura Thornton, a private investment group based in Jersey, Channel Islands.

From Danaher 2 Nov 2009

Sunesis Pharmaceuticals raises $5.0 million through private placement

Sunesis Pharmaceuticals, Inc. today announced the closing of a private placement of $5.0 million of units consisting of convertible preferred stock and common stock warrants on October 30, 2009. This closing constitutes the second tranche of the private placement of up to $43.5 million of Sunesis' securities announced in April 2009.

2 Nov 2009

Valeant Pharmaceuticals announces financial results for the third quarter of 2009

Valeant Pharmaceuticals International today announced third quarter financial results for 2009.

2 Nov 2009

PDI selects Veeva System’s CRM suite of multi-tenant SaaS applications

PDI, Inc., a leading provider of sales and marketing support to U.S. pharmaceutical companies, selected Veeva System’s VBioPharma CRM Primary Care and Special Care Editions, VMobile, and VInsights – all part of the Veeva CRM suite of multi-tenant SaaS applications. This marks PDI’s continued commitment to the technology advances in the world of cloud computing where business spending on SaaS/Cloud applications is expected to rise 22% this year to $9.6 billion, according to Gartner.

2 Nov 2009

"Helmets for Hope" campaign launched to raise epilepsy disorder awareness

November is Epilepsy Awareness Month. The Lennox Gastaut Syndrome Foundation (LGSF) and the American Epilepsy Outreach Foundation (AEOF) has joined with Eisai Pharmaceuticals and Lundbeck Pharmaceuticals to co-host the 1st Annual Helmets for Hope(TM) Campaign.

2 Nov 2009

Perrigo to sell its Israel Consumer Products business to Emilia Group

Perrigo Company today announced that it has signed a definitive agreement to sell its Israel Consumer Products business along with the related production assets in Israel to Emilia Group, a subsidiary of O. Feller Holdings Ltd., for 205 million New Israeli Shekels (approximately $54 million).

2 Nov 2009

Alnylam Pharmaceuticals presents new data from its transthyretin-mediated amyloidosis program

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it presented new pre-clinical research findings from its transthyretin (TTR)-mediated amyloidosis (ATTR) program at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (“The Liver Meeting”).

2 Nov 2009

Positive results from Aeterna Zentaris' AEZS-108 Phase 2 study in ovarian cancer patients

AEterna Zentaris Inc., a global biopharmaceutical company focused on endocrine therapy and oncology, today announced positive efficacy data from a Phase 2 study with its targeted cytotoxic peptide conjugate, AEZS-108 (formerly AN-152), in patients with platinum-resistant and taxane-pretreated ovarian cancer.

2 Nov 2009

Vanda Pharmaceuticals announces financial results for the third quarter of 2009

Vanda Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of clinical-stage products for central nervous system disorders, today announced financial and operational results for the third quarter ended September 30, 2009.

2 Nov 2009